Keyphrases
Pediatric Population
100%
Emicizumab
100%
Bleeding
40%
Thrombin Generation
30%
Trauma Symptoms
20%
Bleeding Risk
20%
Value of Time
20%
Severe Haemophilia A
20%
Laboratory Monitoring
20%
Trauma
10%
Plasma Parameters
10%
Young Infants
10%
Adverse Events
10%
Pediatric
10%
Surgical Procedures
10%
Surgical Intervention
10%
Thrombotic Complications
10%
Safety Efficacy
10%
Prolonged Activated Partial Thromboplastin Time
10%
Activated Partial Thromboplastin Time (aPTT)
10%
Safety Monitoring
10%
Thrombotic Microangiopathy
10%
Efficacy Monitoring
10%
Value Generation
10%
Non-inhibitor
10%
Medicine and Dentistry
Pediatrics
100%
Emicizumab
100%
Bleeding
30%
Thrombin
30%
Partial Thromboplastin Time
20%
Haemophilia A
20%
Ciclonicate
10%
Adverse Event
10%
Surgical Technique
10%
Thrombotic Thrombocytopenic Purpura
10%
Pharmacology, Toxicology and Pharmaceutical Science
Emicizumab
100%
Bleeding
30%
Thrombin
30%
Thromboplastin
20%
Haemophilia A
20%
Adverse Event
10%
Ciclonicate
10%
Thrombotic Thrombocytopenic Purpura
10%
Immunology and Microbiology
Emicizumab
100%
Thrombin
30%
Thromboplastin
20%
Blood Level
10%
Thrombotic Thrombocytopenic Purpura
10%
Neuroscience
Emicizumab
100%
Thrombin
30%
Thromboplastin
20%
Blood Plasma
10%